Boston MedTech Advisors
Dedham, Massachusetts, 02026, United States
NCT Number: NCT06659796
This observational, non-interventional survey study is intended to explore user experiences with the LifeVac airway clearance device, with a particular emphasis on real-world application in choking emergencies in the USA. This study seeks to gather valuable insights from a representative sample of the LifeVac device purchaser base.
The main questions the study aims to answer are:
1. Is the LifeVac device safe for individuals experiencing a choking emergency? 2. Is the LifeVac device successful in removing an obstruction during a choking incident?
Participants: Purchasers of the LifeVac device.
Looking for future studies?
Notify Me1 year and older
All sexes
Observational
Dedham, Massachusetts, 02026, United States
Foreign Body Airway Obstruction (FBAO), commonly referred to as choking, occurs when an aspirated solid or semisolid object becomes lodged in a person's larynx or trachea. If the object is large enough it may cause the complete (or near complete) obstruction of the airway. Without oxygen, brain damage can occur in as soon as four minutes following the event.
LifeVac is a non-powered, non-invasive, single-use airway clearance device developed for resuscitating a victim with an airway obstruction when current choking protocols (basic life support [BLS]) failed to remove the obstruction. The device is intended be used on adults and children, in home and non-home settings, and can be administered by professional/HCP users or laypersons without professional training in a choking emergency.
This observational, non-interventional survey study will be conducted on purchasers of the LifeVac device. The study intends to obtain responses from at least 26 users of the device in each of the two age groups of interest, individuals up to 19 years of age (pediatric) and above 20 years of age (adult), and capture unbiased information on the device users' experience, regardless of its outcome.
Objectives:
Target Population:
Purchasers of the LifeVac device in the USA from 2015 to April 2024.
Data Collection Procedure:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Survey batches: randomly selected sample of 50,000 purchasers (10% of the database).
Number of batches required will be based on response rate.
Exclusion criteria
Removal of airway obstruction during choking emergency
Time frame: Up to 1 week
Occurrence of any serious adverse events (SAE) associated with the use of the LifeVac device.
Time frame: Up to 1 week
Confirm success or partial success in relieving airway obstruction in at least 80% of uses of the device.
Time frame: Up to 1 week
Occurrence of any adverse events (AE) associated with the use of the LifeVac device.
Time frame: Up to 1 week
Explore potential correlations between the outcome of the device use with age of the choking person, the nature of the obstruction, and the environment where the choking incident transpired.
LifeVac, LLC
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06227234
Airway Obstruction, Choking
Calgary, Alberta, Canada
View Trial DetailsNCT06742476
Airway Obstruction, Respiration Disorders
Al Fayyum, Egypt
View Trial DetailsNCT06609499
Airway Obstruction, Respiration Disorders
Radom, Masovian Voivodeship, Poland
View Trial DetailsNCT05748626
Airway Obstruction, Pathological Conditions, Signs and Symptoms
Chicago, Illinois, United States
View Trial Details